推薦產品
等級
pharmaceutical primary standard
API 家族
nitrendipine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
CCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC
InChI
1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
InChI 密鑰
PVHUJELLJLJGLN-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
相關類別
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Nitrendipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
B N Trost et al.
Journal of cardiovascular pharmacology, 6 Suppl 7, S986-S995 (1984-01-01)
Some calcium antagonists, including nitrendipine, were noted to cause a dose-dependent and reversible inhibition of insulin release in certain animal models. Therefore, it is important to know the effects of clinical treatment with calcium antagonists in nondiabetic or diabetic man.
E P Mac Carthy
Journal of cardiovascular pharmacology, 12 Suppl 4, S76-S79 (1988-01-01)
The combination of a beta-adrenoceptor-blocking drug with the dihydropyridine calcium channel antagonist, nitrendipine, has particular therapeutic advantages in the management of hypertension. The beta-blocker reduces any reflex increases in sympathetic nervous system and renin-angiotensin system activity that result from the
U L Hulthén et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S11-S15 (1988-01-01)
The dihydropyridine calcium antagonist nitrendipine offers a pathophysiologically based antihypertensive treatment with a potent dilation of resistance vessels, increased arterial compliance, and an acute natriuretic/diuretic response. Prolonged nitrendipine treatment in essential hypertension is not associated with stimulation of the sympathetic
S K Vanov et al.
Angiology, 39(1 Pt 2), 113-122 (1988-01-01)
To assess the safety of the calcium channel blocker nitrendipine, data from 61 clinical studies conducted in the United States and involving 1,245 patients were reviewed. The drug appeared to be tolerated in the majority of patients and the dropout
A Zanchetti
Journal of cardiovascular pharmacology, 12 Suppl 4, S80-S85 (1988-01-01)
There is evidence from several studies of the clinical usefulness of an antihypertensive regimen combining a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor. The mechanisms of this mutual potentiation between agents of these two classes are probably numerous.
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務